For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AnaptysBio, Inc. (ANAB) been one of those stocks this year?

AnaptysBio Inc. Annual stock financials by MarketWatch. View the latest ANAB financial statements, income statements and financial ratios.

When I think of Arab culture, food is the first thing that comes to mind. We are known to eat fruits and vegetables in all stages of growth: almonds, lima beans, sour green plums and chickpeas, just ...

Multiple analysts have issued price targets for $ANAB recently. We have seen 6 analysts offer price targets for $ANAB in the last 6 months, with a median target of ...

AnaptysBio (ANAB) has drawn attention after a mixed stretch in its share performance, with the stock showing a small 1 day gain, a flat month, and a strong move over the past 3 months. See our latest ...

On Wednesday, AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial ...

AnaptysBio, Inc. receives a "Hold" rating for its U.S.-listed shares. It shows a 16.42% increase in stock market value since the last "Buy" rating. AnaptysBio's immunotherapy portfolio includes ...

AnaptysBio, Inc. (NASDAQ:ANAB) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis. In the 424-patient 2b trial, rosnilimab ...

Following a ~7% rise in the previous session, AnaptysBio (NASDAQ:ANAB) extended gains in the premarket on Wednesday after the biotech announced additional data from a mid-stage trial for its lead ...